In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VHA and UHC Merge Purchasing Programs

Executive Summary

Consolidation in hospital purchasing just took a giant leap forward with the announcement that VHA and University HealthSystems Consortium will create a joint supply chain management program. For suppliers, who have seen other large-scale mergers of customers, the question has become, when is big, too big?

You may also be interested in...



China Provides Patent Linkage In Latest Law Draft - Why Now?

In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.

QUOTED. 15 July 2020. Michael Herzog.

Hedge fund Davidson Kempner is recommending that Qiagen NV renegotiate its planned takeover deal with Thermo Fisher Scientific, arguing that demand for diagnostic fueled by the COVID-19 pandemic makes Qiagen worth more than the price agreed on in March. See what Davidson Kempner’s partner Michael Herzog said about it here.

Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses

Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.

Topics

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel